Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering Sells 15,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 15,000 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $84.26, for a total value of $1,263,900.00. Following the transaction, the chief executive officer now directly owns 478,888 shares of the company’s stock, valued at $40,351,102.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Grant Pickering also recently made the following trade(s):

• On Monday, July 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The shares were sold at an average price of $76.33, for a total value of $199,679.28.
• On Monday, June 24th, Grant Pickering sold 15,000 shares of Vaxcyte stock. The shares were sold at an average price of $75.64, for a total value of $1,134,600.00.
• On Monday, June 3rd, Grant Pickering sold 2,616 shares of Vaxcyte stock. The shares were sold at an average price of $72.06, for a total value of $188,508.96.
• On Thursday, May 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The shares were sold at an average price of $69.43, for a total value of $1,041,450.00.

Vaxcyte Trading Up 1.4 %

Shares of PCVX stock traded up $1.21 on Wednesday, reaching $85.16. 719,337 shares of the company’s stock were exchanged, compared to its average volume of 790,973. Vaxcyte, Inc. has a 52 week low of $44.20 and a 52 week high of $86.14. The stock has a market capitalization of $9.26 billion, a PE ratio of -19.90 and a beta of 0.97. The company’s fifty day simple moving average is $75.25 and its 200 day simple moving average is $70.25.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.28. As a group, sell-side analysts predict that Vaxcyte, Inc. will post -3.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Vaxcyte in a research note on Friday, June 28th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Thursday, June 20th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its position in Vaxcyte by 1,005.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 22,603 shares of the company’s stock valued at $1,419,000 after purchasing an additional 20,558 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Vaxcyte by 12.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 481,119 shares of the company’s stock valued at $30,214,000 after purchasing an additional 52,005 shares in the last quarter. Mutual of America Capital Management LLC bought a new stake in Vaxcyte during the 4th quarter valued at $3,035,000. Natixis Advisors L.P. bought a new stake in Vaxcyte during the 4th quarter valued at $881,000. Finally, Vestal Point Capital LP bought a new stake in Vaxcyte during the 4th quarter valued at $32,970,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.